We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+14.09%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$328M
AUM Growth
-$33M
Cap. Flow
-$50.7M
Cap. Flow %
-15.44%
Top 10 Hldgs %
48.5%
Holding
63
New
10
Increased
14
Reduced
12
Closed
20

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$8.86M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$8.46M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$5.89M
4
VRML
Vermillion, Inc.
VRML
+$4.93M
5
ARVN icon
Arvinas
ARVN
+$4.62M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$11.2M
2
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$10.4M
3
NVTA
Invitae Corporation
NVTA
+$10.3M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$9.31M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.7M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Miscellaneous 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVTX icon
51
Travere Therapeutics
TVTX
$6.36B
– –
-205,000
Closed -$4.64M
TVRD
52
Tvardi Therapeutics
TVRD
$24M
– –
-5,556
Closed -$3.92M
SWAV
53
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-92,100
Closed -$3.08M
CBAY
54
DELISTED
Cymabay Therapeutics
CBAY
– –
-550,000
Closed -$7.3M
NVTA
55
DELISTED
Invitae Corporation
NVTA
– –
-440,000
Closed -$10.3M
MRTX
56
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-105,000
Closed -$7.7M
ACOR
57
DELISTED
Acorda Therapeutics
ACOR
– –
-2,208
Closed -$3.52M
FOMX
58
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-180,000
Closed -$675K
DERM
59
DELISTED
Dermira, Inc.
DERM
– –
-400,000
Closed -$5.42M
HZNP
60
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-185,000
Closed -$4.89M
CMTA
61
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
– –
-400,130
Closed -$10.4M
LJPC
62
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-60,000
Closed -$386K
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2019 Portfolio in Review

As of Q2 2019, Opaleye Management held 63 positions worth $328M, down 9.1% from $361M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Opaleye Management withdrew a net $50.7M in Q2 2019, closing 20 positions and reducing 12 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $11.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Lexicon Pharmaceuticals worth $9.31M.

  • Opaleye Management's largest Q2 2019 buy was Lexicon Pharmaceuticals: 1,480,000 shares worth $9.31M.
  • Opaleye Management added most to Ocular Therapeutix in Q2 2019, an estimated $3.89M increase.
  • Opaleye Management's biggest Q2 2019 reduction was Axogen, cutting an estimated $4.28M.
  • Opaleye Management fully exited Ascendis Pharma A/S in Q2 2019, selling an estimated $11.2M.
  • Opaleye Management's ten largest holdings make up 49% of its $328M portfolio in Q2 2019.
  • Opaleye Management opened 10 new positions and closed 20 in Q2 2019.
  • Opaleye Management's portfolio value fell 9.1% quarter-over-quarter to $328M.

Based on Opaleye Management's 13F filing for Q2 2019, filed 14 Aug 2019.